SCAP and the Small-Cap Dividend Screen: Quality Filter or Marketing Story?

The competitor pitch is straightforward: screen small-cap stocks for dividends and balance-sheet discipline, and you've filtered out the junk without needing to trust earnings forecasts. The Infrastructure Capital Small Cap Income ETF (SCAP) is held up as the proof point.

The question is whether SCAP's actual portfolio matches that story, or whether the overlay mechanics — covered calls, modest leverage, a 2.20% expense ratio — are doing the heavy lifting while the dividend screen gets the credit.

The dividend screen is just an earnings filter in disguise

The Fidelity institutional note from early 2026 put the number on the table: approximately 41% of Russell 2000 components did not generate earnings. That's not a rounding error — it means nearly half the small-cap universe is unprofitable. Growth-oriented companies, sure, but companies whose market value isn't backed by current profitability.

Requiring a sustained cash dividend is a way of filtering those out without saying it directly. You can't pay a dividend if you're not earning. The screen isn't wrong; it's just not as novel as the marketing implies. It's a profitability gate wearing a different label.

That matters because the way you frame the filter determines what you think you're buying. If you think you're buying income, you'll be disappointed — most of SCAP's equity positions yield between 0.7% and 1.7%. If you think you're buying earnings discipline in a sea of small-cap speculation, the logic holds.

The portfolio tells a messier story

SCAP's top holdings as of mid-2026 show three very different factor profiles. The fact that they sit in the same fund is worth examining, because different factor profiles should produce different roles in a portfolio.

Toll Brothers (TOL) — The one that fits.

Toll Brothers is the holding that validates the screen. PE of 11.3x, EV/EBITDA of 9.7x, free cash flow growth of 68% year-over-year, net debt of $1.68 billion against $8.49 billion in equity (debt-to-equity of 32.8%). The company has paid dividends for eight consecutive years, growing them for four straight years. The payout ratio sits at 7.5%, meaning the dividend is trivial relative to earnings power and has enormous runway.

Compared to homebuilder peers D.R. Horton (PE 13.8x, yield 1.5%) and PulteGroup (PE 13.1x, yield 0.8%), Toll Brothers trades at a discount while delivering stronger free cash flow growth and a better leverage profile. It's the holding that makes the screening thesis look good.

Huntington Ingalls (HII) — Dividend quality, but the balance sheet is heavier.

Huntington Ingalls is the defense contractor in SCAP's portfolio. PE of 19.3x, dividend yield of 1.69%, 12 consecutive years of dividend growth. On the income side, it passes every test.

On the balance sheet, the numbers are different. Net debt of $2.69 billion, debt-to-equity of 50.9%, free cash flow that turned negative last year (down 112.7% to -$85 million). Capital expenditures of $432 million ate through most of the $347 million in operating cash flow. The company is investing heavily in defense production capacity, which is a strategic choice, not a failure, but it means the balance-sheet filter isn't as clean as the marketing suggests.

Compared to defense peers Lockheed Martin (PE 21.6x, yield 2.3%) and Northrop Grumman (PE 18.1x, yield 1.6%), Huntington Ingalls trades at a modest discount. The valuation support is there. The cash-flow conversion during heavy investment periods is what you need to watch.

Halozyme Therapeutics (HALO) — The outlier that breaks the narrative.

Here's where the screening story runs into friction. Halozyme, one of SCAP's largest equity positions, doesn't pay a dividend. Zero consecutive dividend years. Zero dividend per share in the last fiscal year. The stock is up 53.2% year-to-date and surged 20.2% in a single session this week, sitting at a 52-week high of $103.30.

Halozyme pays no dividend but generates $806 million in trailing free cash flow, up 49% year-over-year. Its balance sheet is technically strained — $2.43 billion in debt against only $144 million in equity, a debt-to-equity ratio of 1,495%. But the cash generation is extraordinary for a biotech, and the company is using leverage to buy back capital while maintaining strong liquidity (current ratio of 271%).

If the screening mandate is sustained dividends, Halozyme shouldn't be here. The fact that it is means SCAP's strategy is broader than the dividend screen suggests — and that's fine, so long as investors understand what they're actually buying. The fund also deploys convertible and preferred securities for yield, which complicates the pure-equity narrative.

Herc Holdings — Structural leverage in disguise.

The competitor article notes Herc Holdings' net debt to EBITDA at 6.3x and calls it "structurally higher leverage due to hard-asset fleet." That's an understatement. Herc is an equipment rental company that recently completed its acquisition of H&E Equipment Services, and the business model inherently requires heavy balance sheets to own and maintain the fleet. Q2 2026 revenue grew 20%, adjusted EBITDA was solid, but GAAP net income was only $19 million ($0.57 per share) against adjusted net income of $48 million ($1.43 per share).

The gap between GAAP and adjusted earnings in a capital-intensive business is normal — depreciation loads are real. But it's another reminder that "balance sheet strength" means something different depending on the industry. A 6.3x net debt/EBITDA ratio is fine for equipment rental with predictable cash flows and tangible collateral. It would be alarming for a software company.

The real question: do the overlay strategies earn the fee?

SCAP charges a 2.20% expense ratio. That's above average for an equity ETF. The fund justifies it with three things the dividend screen doesn't provide:

1. Covered call writing against individual positions — generates income but caps upside on the names where you write them
2. Modest leverage of 5% to 20% — amplifies both returns and drawdowns
3. Active security selection — the GARP (growth at a reasonable price) analysis layered on top of the dividend screen

The fund's reported NAV return of +26.7% through June 30, 2026, beats the Russell 2000's 19.25% year-to-date gain. But with $20 million in assets, SCAP is a micro-fund where a few concentrated positions can move the needle dramatically. Halozyme's 53% YTD surge alone has outsized portfolio impact.

Small caps also led the market in 2026. The Russell 2000's +19% year-to-date outpaces the S&P 500's +11%, and the Federal Reserve's rate cuts from the prior year have improved the refinancing environment for small-cap issuers that borrow at floating rates. SCAP is riding a tailwind that helps every small-cap strategy.

What the factor stack actually says

Screening small caps for dividends is a legitimate quality filter. It eliminates the roughly 41% of the Russell 2000 that doesn't generate earnings. That's the real insight, stripped of marketing language.

But SCAP's portfolio shows that the fund's actual edge comes from the overlay strategies and active selection, not from the dividend screen alone. Halozyme has no dividend. Herc has structural leverage. The fund's best-performing holding this year doesn't pay investors a cent in distributions.

The portfolio logic is barbell-adjacent: Toll Brothers and Huntington Ingalls provide the dividend and earnings discipline, while Halozyme provides cash-generative growth at a price that's running hot. That's a defensible structure. It's just not the story the dividend screen tells.

What would change the thesis: If the dividend-paying names in SCAP's portfolio start losing their factor edge — declining growth, deteriorating margins, or valuation compression relative to peers — the income sleeve of the strategy would weaken. If the overlay strategies (calls and leverage) produce alpha after the 2.20% fee in a flat market environment, that would validate the active approach. If they don't, the dividend screen alone doesn't justify the cost.

Portfolio role: SCAP belongs in a small-cap quality sleeve, not a pure income sleeve. The yield is incidental; the earnings discipline is the structural play. If you need current income, there are cheaper index vehicles. If you want small-cap exposure filtered for profitability and enhanced with active overlay strategies, the factor stack supports it — but know what you're actually paying for.